Comparison
Fisetin vs. Quercetin
Fisetin or quercetin – which senolytic is further along?
The short answer
Both are marketed as senolytics, i.e. as agents that selectively eliminate aged cells – and for both, exactly that has not been shown in humans. Fisetin now has several small randomized trials with surrogate markers such as inflammatory values; a randomized osteoarthritis trial with 75 participants found no difference in side effects and inflammatory markers, and the lifespan extension seen in mice was not confirmed in the independent Interventions Testing Program. Quercetin has more human data, but on something else: a reduction in systolic blood pressure of 2 to 3 mmHg, consistent across three meta-analyses. The regulatory finding is telling – EFSA rejected precisely the claims with which quercetin is advertised, for lack of evidence. In the senolytic context, the combination of dasatinib and quercetin is further along than either single substance.
The numbers side by side
| Axis | Fisetin | Quercetin | Difference |
|---|---|---|---|
| Human evidenceHow much and how good the data in humans are | 4 | 6 | Quercetin better studied |
| MechanismHow well the chain of action is understood | 4 | 6 | Quercetin better studied |
| Safety dataHow well safety has been studied – not how safe it is | 3 | 6 | Quercetin better studied |
| Hype gap10 means: the advertising stays level with the data | 1 | 4 | Quercetin closer to the data |
| Track record of useHow much documented use in humans exists – does not measure whether it works | 4 | 6 | Quercetin in use longer |
| Rating | Thin human evidence · Supported, with caveats | ||
“Track record of use” measures how long and how widely something has been used in humans – not whether it works. The BK-Score is a subjective assessment by Biohacking Kompakt based on published scoring rules (German). It is not a scientific rating, not the consensus of a professional society and not a medical recommendation.
Why these numbers
Fisetin
The gap between mouse and human is the whole finding here: the senolytic effect is documented in cell culture and in mice (Yousefzadeh 2018), but was not confirmed in the independent Interventions Testing Program – no lifespan extension, no decrease in p16 in kidney, brain and liver (Harrison, GeroScience 2024). In humans, there are now several small RCTs with surrogate markers: IL-8 lowered in 37 colorectal cancer patients (Farsad-Naeimi 2018), IL-6 and HOMA-IR in 44 men with obesity (Alipour 2026), better NIHSS scores in stroke patients who received late thrombolysis (Wang 2019). The randomized osteoarthritis trial NCT04210986 with 75 participants found no difference over a mean of 12 months in side effects (28 versus 33 people affected) and senescence-associated inflammatory markers; the often-cited ROPE trial (NCT04770064), by contrast, was withdrawn. That oral administration reduces senescent cells in humans has not been shown; AFFIRM at the Mayo Clinic has been running since 2018. The safety data are limited to short, intermittent regimens.
Quercetin
Blood pressure is the most robust field: three meta-analyses find the same effect of the same magnitude – Serban et al. (J Am Heart Assoc 2016, 7 RCTs, 587 patients) 3.04 mmHg systolic, Huang et al. (Nutr Rev 2020, 17 RCTs, 896 participants) 3.09 mmHg, Popiolek-Kalisz & Fornal (Curr Probl Cardiol 2022, 10 RCTs, 841 participants) 2.38 mmHg. From 500 mg daily, the effect is 4.45 mmHg; below that, it is 1.59 mmHg and no longer significant; the authors stress, however, that the direct comparison of the dose groups showed no significant difference. In sport, the effect is statistically present and practically irrelevant: Pelletier et al. (2013) find 0.09% in trained people, with a spread of 2.15%. The senolytic narrative does not carry this side: in all five human studies, quercetin was given alongside the prescription-only drug dasatinib, the only phase 2 trial (Farr et al., Nat Med 2024, 60 women) missed its primary endpoint, and in Alzheimer’s patients, quercetin was not detectable in the cerebrospinal fluid at all. The regulatory situation is clear: quercetin does not appear in the Union list of authorised health claims (Regulation (EU) No 432/2012); EFSA assessed four claims on it in 2011 (ID 1647, 1844, 1845, 1846), and none is on the positive list today.
Frequently asked questions
What does senolytic actually mean?
Aged cells no longer divide, but they do not die either, and they release pro-inflammatory substances. Senolytics are supposed to remove them selectively. In mice, this works and extends healthspan; in humans, only a few small studies have so far shown that the burden of such cells decreases measurably at all.
Is dasatinib plus quercetin supported?
It is the most advanced senolytic combination – with studies in diabetic kidney disease, pulmonary fibrosis, Alzheimer’s disease and bone metabolism. All are small and mostly designed around safety and biomarkers. Dasatinib is a cancer drug with a corresponding side-effect profile.
Why does quercetin have a poor hype gap despite the studies?
Because the studies and the advertising talk about different things. What is supported is a small blood pressure effect of 2 to 3 mmHg systolic. What is advertised is immune strengthening, DNA protection and senolysis – none of these claims is on the EU positive list, and the only phase 2 trial on senolysis, in combination with dasatinib, missed its primary endpoint.
See all 255 ratings in the ranking (German app)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in a doctor's hands.